Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Sustained reduction of catheter-associated bloodstream infections with enhancement of catheter bundle by chlorhexidine dressings over 11 years.

Eggimann P, Pagani JL, Dupuis-Lozeron E, Ms BE, Thévenin MJ, Joseph C, Revelly JP, Que YA.

Intensive Care Med. 2019 Jun;45(6):823-833. doi: 10.1007/s00134-019-05617-x. Epub 2019 Apr 17.

2.

Isavuconazole brain penetration in cerebral aspergillosis.

Lamoth F, Mercier T, André P, Pagani JL, Pantet O, Maduri R, Guery B, Decosterd LA.

J Antimicrob Chemother. 2019 Jun 1;74(6):1751-1753. doi: 10.1093/jac/dkz050. No abstract available.

PMID:
30753519
3.

Reply to Sorooshian and Snow, "Is Alternate-Day Therapeutic Drug Monitoring in the Intensive Care Unit Not Intensive Enough?"

Fournier A, Eggimann P, Pantet O, Pagani JL, Dupuis-Lozeron E, Pannatier A, Sadeghipour F, Voirol P, Que YA.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01343-18. doi: 10.1128/AAC.01343-18. Print 2018 Oct. No abstract available.

4.

Impact of Real-Time Therapeutic Drug Monitoring on the Prescription of Antibiotics in Burn Patients Requiring Admission to the Intensive Care Unit.

Fournier A, Eggimann P, Pantet O, Pagani JL, Dupuis-Lozeron E, Pannatier A, Sadeghipour F, Voirol P, Que YA.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01818-17. doi: 10.1128/AAC.01818-17. Print 2018 Mar.

5.

Staphylococcus aureus carriage at admission predicts early-onset pneumonia after burn trauma.

Fournier A, Voirol P, Krähenbühl M, Bonnemain CL, Fournier C, Dupuis-Lozeron E, Pantet O, Pagani JL, Revelly JP, Sadeghipour F, Eggimann P, Que YA.

Eur J Clin Microbiol Infect Dis. 2017 Mar;36(3):523-528. doi: 10.1007/s10096-016-2828-0. Epub 2016 Nov 4.

PMID:
27815777
6.

Antibiotic consumption to detect epidemics of Pseudomonas aeruginosa in a burn centre: A paradigm shift in the epidemiological surveillance of Pseudomonas aeruginosa nosocomial infections.

Fournier A, Voirol P, Krähenbühl M, Bonnemain CL, Fournier C, Pantet O, Pagani JL, Revelly JP, Dupuis-Lozeron E, Sadeghipour F, Pannatier A, Eggimann P, Que YA.

Burns. 2016 May;42(3):564-70. doi: 10.1016/j.burns.2015.10.030. Epub 2015 Dec 23.

PMID:
26708236
7.

Prognostication of Mortality in Critically Ill Patients With Severe Infections.

Que YA, Guessous I, Dupuis-Lozeron E, de Oliveira CRA, Oliveira CF, Graf R, Seematter G, Revelly JP, Pagani JL, Liaudet L, Nobre V, Eggimann P.

Chest. 2015 Sep;148(3):674-682. doi: 10.1378/chest.15-0123.

PMID:
26065577
8.

Low C-reactive protein values at admission predict mortality in patients with severe community-acquired pneumonia caused by Streptococcus pneumoniae that require intensive care management.

Que YA, Virgini V, Lozeron ED, Paratte G, Prod'hom G, Revelly JP, Pagani JL, Charbonney E, Eggimann P.

Infection. 2015 Apr;43(2):193-9. doi: 10.1007/s15010-015-0755-0. Epub 2015 Mar 3.

PMID:
25732200
9.

Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients.

Fournier A, Eggimann P, Pagani JL, Revelly JP, Decosterd LA, Marchetti O, Pannatier A, Voirol P, Que YA.

Burns. 2015 Aug;41(5):956-68. doi: 10.1016/j.burns.2015.01.001. Epub 2015 Feb 10.

PMID:
25678084
10.

Preventing invasive candida infections. Where could we do better?

Eggimann P, Que YA, Revelly JP, Pagani JL.

J Hosp Infect. 2015 Apr;89(4):302-8. doi: 10.1016/j.jhin.2014.11.006. Epub 2014 Dec 16. Review.

11.

Effective treatment of invasive Aspergillus fumigatus infection using combinations of topical and systemic antifungals in a severely burned patient.

Fournier A, Pantet O, Guerid S, Eggimann P, Pagani JL, Revelly JP, Hauser PM, Marchetti O, Fontanella S, Letovanec I, Ravat F, Berger MM, Pannatier A, Voirol P, Que YA.

J Burn Care Res. 2015 Mar-Apr;36(2):e85-9. doi: 10.1097/BCR.0000000000000143.

PMID:
25127025
12.

Assessment of panobacumab as adjunctive immunotherapy for the treatment of nosocomial Pseudomonas aeruginosa pneumonia.

Que YA, Lazar H, Wolff M, François B, Laterre PF, Mercier E, Garbino J, Pagani JL, Revelly JP, Mus E, Perez A, Tamm M, Rouby JJ, Lu Q, Chastre J, Eggimann P.

Eur J Clin Microbiol Infect Dis. 2014 Oct;33(10):1861-7. doi: 10.1007/s10096-014-2156-1. Epub 2014 May 24.

PMID:
24859907
13.

Thymoma, immunodeficiency, and herpes simplex virus infections.

Méan M, Schaller MD, Asner S, Meylan P, Pagani JL, Tarr P, Eggimann P.

Med Mal Infect. 2009 May;39(5):344-7. doi: 10.1016/j.medmal.2009.01.008. Epub 2009 Mar 9.

PMID:
19269757
14.

Management of catheter-related infection.

Pagani JL, Eggimann P.

Expert Rev Anti Infect Ther. 2008 Feb;6(1):31-7. doi: 10.1586/14787210.6.1.31. Review.

PMID:
18251662
15.

[Management of catheter-related infection: recommendations for clinical practice].

Pagani JL, Revelly JP, Chiolero R, Eggimann P.

Rev Med Suisse. 2007 Dec 12;3(137):2834, 2836-9. Review. French.

PMID:
18225840
16.

[Severe acute asthma].

Pagani JL, Oddo M, Schaller MD.

Rev Med Suisse Romande. 2004 Jun;124(6):333-6. Review. French.

PMID:
15293440
18.

Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients.

Csajka C, Décosterd LA, Buclin T, Pagani JL, Fattinger K, Bille J, Biollaz J.

Eur J Clin Pharmacol. 2001 Dec;57(10):723-7.

PMID:
11829202
19.

Monitoring responses to antiretroviral treatment in human immunodeficiency virus type 1 (HIV-1)-infected patients by serial lymph node aspiration.

Bürgisser P, Spertini F, Weyrich-Suter C, Pagani JL, Meylan PR.

J Infect Dis. 1997 May;175(5):1202-5.

PMID:
9129086
20.

Typing Candida albicans oral isolates from human immunodeficiency virus-infected patients by multilocus enzyme electrophoresis and DNA fingerprinting.

Boerlin P, Boerlin-Petzold F, Goudet J, Durussel C, Pagani JL, Chave JP, Bille J.

J Clin Microbiol. 1996 May;34(5):1235-48.

21.

Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters.

Sanglard D, Kuchler K, Ischer F, Pagani JL, Monod M, Bille J.

Antimicrob Agents Chemother. 1995 Nov;39(11):2378-86.

22.

Cluster of oral atypical Candida albicans isolates in a group of human immunodeficiency virus-positive drug users.

Boerlin P, Boerlin-Petzold F, Durussel C, Addo M, Pagani JL, Chave JP, Bille J.

J Clin Microbiol. 1995 May;33(5):1129-35.

23.

Transmission of oral Candida albicans strains between HIV-positive patients.

Boerlin P, Addo M, Boerlin-Petzold F, Durussel C, Pagani JL, Chave JP, Bille J.

Lancet. 1995 Apr 22;345(8956):1052-3. No abstract available.

PMID:
7723523

Supplemental Content

Loading ...
Support Center